Today's MedImmune is clearly positioned as one of the world's leading biotech
companies. With one of the largest pipelines in the industry, we currently have
over 100 research projects and clinical product candidates in our portfolio. We
aim to deliver several promising new biologics to the market by continuing our
leadership in the area of infectious diseases; playing a key role in
inflammation, cancer, and autoimmune
and respiratory diseases; and building on our expertise in other areas to
create a world-class focus in neuroscience, cardiovascular, and
gastrointestinal diseases.
Through cutting-edge technology MedImmune is:
-
Accelerating the development of novel
antibody
or antibody-like therapeutic and preventive medicines, and many non-traditional
methods may be developed for disease intervention
-
Looking to engineer novel properties, such as
effector function
improvement, into antibodies to enhance their potency
-
Exploring the possibility of generating long-lasting antibody therapy so that
dosing frequency can be reduced
-
Developing bi-specific antibodies, polyspecific antibodies, or polyclonal
antibodies to target multiple disease mediators to increase drug efficacy while
maintaining an appropriate safety profile.
At MedImmune, our dedicated teams constantly seek innovative ways to bring
improvement to existing biologics, as well as create extraordinary new ways of
thinking in the ever-evolving world of biopharmaceuticals. From vaccinations
that help prevent disease to therapeutics designed to improve lives for
seriously ill patients, our focus is to provide the best possible solutions.